PatientsLikeMe and the FDA will explore the potential of patient-generated data to inform regulatory review activities related to risk assessment and risk management.
The abuse-deterrent labeling approval for prescription painkillers means they are formulated to make it tougher for patients to abuse.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
A study in the British Medical looked at company press releases found that they frequently held back information about why the FDA rejected a drug.
Axovant Sciences with Alzheimer's drug in Phase 3 development had a monster IPO, prompting fears of a biotech bubble.
Critics say that however well-intentioned the voucher program is, it could have some unintended consequences.
Accenture predicts FDA regulated digital health solutions could improve medication adherence and reduce ER visits saving $100 billion. Pharma companies' push for a price lock-in for Trans Pacific trade deal.
Executives at the ViVE Payer Insights event earlier this year discussed prior authorization, AI, value-based care and the role of tech to help achieve their goals.
There is enormous untapped potential in the N-of-1 clinical trial.
Bristol-Myers Squibb revealed results of Phase 3 study of combined melanoma treatment that could be a cancer treatment breakthrough, but comes with a big price tag and side effects.
Johnson and Johnson accepted an offer from Cardinal Health to acquire vascular medical device producer, the FDA wins a lawsuit over granting companies the ability to produce a generic model of an orphan drug.
Express Scripts, a prescription drug benefit manager, is seeking payment deals with pharma companies that would set drug prices based on how well their cancer treatments work.
A new eBook from HLTH and MedCity News captures how health insurers and their partners are using health tech to improve the patient experience.
The vast majority of life sciences venture capital went to biotechnology, a PricewaterhouseCoopers report finds.
Drug costs are astronomical – this we know. But we don’t have a transparent, informed way of calculating – or understanding – the true costs of drug development, argued Dr. Jerry Avorn, a professor of pharmacoeconomics at Harvard University, in this week’s New England Journal of Medicine. And this ignorance may be helping big pharma inflate the price of drugs. He […]
The 21st Century Cures bill designed to speed up biomedical innovation continues to move forward after being passed by the The House Energy and Commerce health subcommitte.
Many of the apps that pharma companies are developing to support conditions or specific drugs and diagnostics are either only available outside the U.S. or are still being evaluated in pilot studies. A specialist drug developer rolled out an app in December to support its drug to treat people for opioid abuse. The idea is […]
There's some pretty good reasons to not let the market decide the future of cancer treatments.